mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity
Published on 23 April 2026
Dr McKay discusses the study she presented at ASCO GU 2026 which looked at data from the IRONMAN advanced prostate cancer registry.
This international real-world study examined how treatments are sequenced before and after the development of metastatic castration-resistant prostate cancer (mCRPC) across 15 countries between 2018–2022.
The study found an underuse of AR pathway inhibitors before mCRPC develops, despite their post-mCRPC dominance. Treatment patterns vary internationally, and the findings highlight an unmet need for earlier optimisation of therapy sequencing in advanced prostate cancer.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.